sabato, 15 giugno 2024
Medinews

Notizie AIOM – anno XVI n. 670

9 Aprile 2018

6 aprile 2018 – Chiusura Registro di monitoraggio Sorafenib (Bayer AG) (RCC)

Leggi tutto
9 Aprile 2018

6 aprile 2018 – Chiusura Registro di monitoraggio Sorafenib (Bayer AG) (epatocarcinoma)

Leggi tutto
9 Aprile 2018

3 Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial

Reduction of adjuvant treatment duration may decrease toxicities without loss of efficacy in stage III colon cancer. This could offer clear advantages to patients and health care providers. In International Duration Evaluation of Adjuvant Chemotherapy (IDEA) France, as part ...
Leggi tutto